US › Healthcare

Reviva Pharmaceuticals Holdings Inc. (RVPH)

US · Healthcare · Biotechnology

$0.52+29.97%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-3.2M
Profit YoY
+50.3%
EPS
$-0.46
EPS estimate
$-0.29

EPS came in at -0.46 against a street estimate of -0.29 — a miss of 58.6%.

Key statistics

Market cap
$5.7M
Forward P/E
0.0
P/B
0.33
Book value
$1.36
EPS (TTM)
$-3.33
52-week high
$17.20
52-week low
$0.26
50-day MA
$0.57
200-day MA
$4.33
Beta
0.47

Analyst view

Analysts rate Reviva Pharmaceuticals Holdings Inc. a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $17.50.

Shareholding

Insiders
7.73%
Institutions
12.84%

Largest institutional holders

FundStake
Millennium Management LLC6.06%
Highbridge Capital Management, LLC5.81%
Armistice Capital, LLC4.52%
GSA Capital Partners LLP2.00%
Vanguard Capital Management, LLC0.90%
Warberg Asset Management LLC0.69%
Geode Capital Management, LLC0.56%
Renaissance Technologies Corp0.33%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Reviva Pharmaceuticals Holdings Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.